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Aspergillus fumigatus is an airborne opportunistic fungal pathogen responsible for
severe infections. Among them, invasive pulmonary aspergillosis has become a
major concern as mortality rates exceed 50% in immunocompromised hosts. In
parallel, allergic bronchopulmonary aspergillosis frequently encountered in cystic fibrosis
patients, is also a comorbidity factor. Current treatments suffer from high toxicity which
prevents their use in weakened subjects, resulting in impaired prognostic. Because
of their low toxicity and high specificity, anti-infectious therapeutic antibodies could
be a new alternative to conventional therapeutics. In this study, we investigated the
potential of Chitin Ring Formation cell wall transglycosylases of A. fumigatus to be
therapeutic targets for therapeutic antibodies. We demonstrated that the Crf target
was highly conserved, regardless of the pathophysiological context; whereas the
CRF1 gene was found to be 100% conserved in 92% of the isolates studied, Crf
proteins were expressed in 98% of the strains. In addition, we highlighted the role
of Crf proteins in fungal growth, using a deletion mutant for CRF1 gene, for which
a growth decrease of 23.6% was observed after 48 h. It was demonstrated that
anti-Crf antibodies neutralized the enzymatic activity of recombinant Crf protein, and
delayed fungal growth by 12.3% in vitro when added to spores. In a neutropenic
rat model of invasive pulmonary aspergillosis, anti-Crf antibodies elicited a significant
recruitment of neutrophils, macrophages and T CD4 lymphocytes but it was not
correlated with a decrease of fungal burden in lungs and improvement in survival.
Overall, our study highlighted the potential relevance of targeting Crf cell wall protein
(CWP) with therapeutic antibodies.
Keywords: Aspergillus, fungi, invasive pulmonary aspergillosis, cell wall, Crf1, Crh5, glycosyltransferase,
monoclonal antibody
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INTRODUCTION
Nowadays, medical practice is increasingly confronted with
infectious pathology issues. In such a context, fungal diseases,
from Candida sepsis in intensive care unit context, to airway
mycoses which are the underlying cause of many cases of
severe asthma and sinusitis, are a major concern (Porter et al.,
2014; Jacobs et al., 2015). Invasive pulmonary aspergillosis
(IPA) and allergic bronchopulmonary aspergillosis (ABPA) are
both airborne diseases caused by ubiquitous molds of the
Aspergillus genus, and primarily by A. fumigatus (Desoubeaux
et al., 2014). IPA is responsible for high mortality rates ranging
from 28.5 to 55% in immunocompromised hosts (Bitar et al.,
2014; Taccone et al., 2015), following hematopoietic stem
cell transplantation, solid organ transplantation or anticancer
chemotherapy (Desoubeaux et al., 2014). Encountered in about
1.5% of patients with asthma (Latgé, 1999), ABPA is also
encountered in 1–15% of patients suffering from cystic fibrosis
(CF) (Stevens et al., 2003), for which massive colonization and
subsequent hypersensitivity to Aspergillus spores are comorbidity
factors, especially in cases of lung transplantation.
Together with an incomplete understanding of aspergillosis
pathophysiology, the high fatality rate is partly caused by the lack
of efficient antifungal therapies and the difficulty of establishing
a reliable diagnosis. Azole- or polyene-based treatments suffer
from numerous toxic side effects in liver, kidney or blood,
which can prevent their use, and especially so in weakened
patients. In addition, a progression in acquired resistance to azole
treatments has been reported recently (Howard et al., 2009). In
contrast, the echinocandin class shows lower toxicity, but displays
only a fungistatic activity against Aspergillus species. Therefore,
echinocandins are rarely used in first line in cases of aspergillosis
(Walsh et al., 2008).
In view of these considerations, anti-infectious therapeutic
antibodies are emerging as a promising alternative to
conventional treatments (Kuhn et al., 2016; Sécher et al., 2018).
They present the advantage of being very specific, therefore
limiting unpredicted side effects. Some of them have already
reached the pharmaceutical market, e.g., against respiratory
syncytial virus (palivizumab), anthrax toxin (raxibacumab and
obiltoxaximab) or Clostridium difficile toxin (bezlotoxumab), and
a large number are currently under research and development
process (Wagner and Maynard, 2018). Among them, a few have
been developed against fungi, mostly against yeasts, and provided
quite encouraging results (Matthews et al., 1995; Chaturvedi
et al., 2005, 2009; Bugli et al., 2013).
An antibody fragment (MS112-IIB1) directed against the
Chitin ring formation 2 (Crf2) protein of A. fumigatus was
initially developed for diagnosis purposes (Schütte et al., 2009).
Encoded by CRF1 gene, the Crf protein family contains three
protein variants: Crf2 protein, amino acids (333 aa) long, Asp f9
protein (292 aa), first identified as an allergen using serum from
Aspergillus-allergic patients (Crameri and Blaser, 1996), and Crf1
(395 aa, also named Crh5). Crf1 protein is the only member of the
Crf family with a predicted glycosylphosphatidylinositol (GPI)
anchor (Arroyo et al., 2007), and has been shown to induce a
cross-protection between A. fumigatus and C. albicans infection
(Stuehler et al., 2011). Classified into the glycoside hydrolase
family 16 (CAZy database), Crf proteins (Crf1, Crf2, Asp f9)
are actually orthologs of Crh proteins in A. fumigatus (Crh1,
Crh2, Crh3, Crh4), in C. albicans (Crh11, Crh12, Utr2) and
Saccharomyces cerevisiae (Crh1, Crh2, Crr1) yeasts, and share a
highly conserved catalytic domain (Arroyo et al., 2016). In yeasts,
Crh proteins have been characterized with transglycosylase
activity involved in the linkage of chitin to β(1-3)glucans and
β(1-6)glucans residues in the cell wall (Cabib, 2009). In contrast,
little is known about the conservation and the role of Crf proteins
in A. fumigatus, despite quite a high structural similarity with
Crh. Although β(1-6)glucans are not present in A. fumigatus, Crf
may be involved in the remodeling of the cell wall as well, and
therefore in the growth and the virulence of the fungus.
In this study, we highlighted the high conservation rate
of Crf proteins in clinical strains of A. fumigatus and
their potential as a therapeutic target. We demonstrated that
anti-Crf MS112-IIB1 antibody might be a new option in the
treatment of A. fumigatus-associated diseases, through its ability
to neutralize Crf proteins in vitro. Moreover, spraying this
antibody in a neutropenic rat model of IPA induced a significant
recruitment of immune cells in vivo, but did not statistically
increase the overall survival.
MATERIALS AND METHODS
Strains
Clinical Strains
Forty-nine Aspergillus fumigatus strains were recovered at the
CHRU of Tours (France): one in 2005 (referred to as “Crf+,”
registered in the WFCC-MIRCEN World Data Centre for
Microorganisms – Marseille, France – under no. BRFM 1827),
and 48 between September and December 2015. Strains were
either isolated from respiratory samples of patients without
development of any Aspergillus disease (n = 38), or affected by
ABPA (n = 4), IPA (n = 3), aspergilloma (n = 1), Aspergillus
bronchitis (n = 1), or from environmental contamination (n = 2).
Engineered Strains
Ku80 Wild Type (WT) and Ku80 Crf knock-out mutant (1CRF1)
strains were gently given by Dr. Daan Van Aalten at the
University of Dundee, United Kingdom (Fang et al., 2015). Their
engineering was performed based on the methods described by
D’Enfert (1996) and Da Silva Ferreira et al. (2006).
Culture Conditions
All fungal strains were initially grown on Sabouraud gentamicin
chloramphenicol agar plates (Thermo Fisher Scientific, Dardilly,
France) at 35◦C for 72 h. Spores were harvested using 0.05%
(v/v) Triton X100 in phosphate-buffered saline (PBS), followed
by two washes in PBS with centrifugation at 1,700 × g for
10 min, and re-suspended in PBS. Depending on the different
protocols, spore concentration was adjusted in RPMI liquid
medium (RPMI 1640, MOPS, glucose) or PBS (animal protocols)
after a measurement of the absorbance at 530 nm followed by
counting in hemocytometer cell.
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Antibodies
Bio-Engineering of scFv and scFv-Fc
Anti-Crf2 antibody MS112-IIB1 was produced as scFv as
previously described (Schütte et al., 2009). Production of scFv-Fc
with a human IgG1 Fc part was performed using the vector
pCSE2.6-hIgG1-Fc-XP as described before (Jäger et al., 2013).
Production of IgG1
Variable regions from anti-Crf2 antibody MS112-IIB1 scFv
coding plasmid were amplified by PCR to introduce BbsI
restriction sites at their extremities. These fragments were
used to construct a vector expressing a full-length human
IgG1 using Golden Gate Assembly (Engler et al., 2008). The
recipient vector was designed as described in Li et al. (2007),
using the backbone of pFUSE-hIgG1-Fc1 (Invivogen, Toulouse,
France) (Supplementary Figure S1B). The plasmid contains
both IgG1 genes assembled as a bicistronic construct under the
control of the hEF1 promoter before the light chain (Kappa
constant domain), followed by an Encephalomyocarditis virus
internal ribosome entry site to mediate heavy chain translation.
The plasmids obtained were replicated in E. coli One Shot
Top10 F’ (Thermo Fisher Scientific, Villebon-sur-Yvette, France)
according to the supplier recommendations. Transformed
bacteria were amplified in liquid medium LB low salt with Zeocin
(Invivogen). Plasmids were then purified using Nucleobond Xtra
Maxi EF 10 kit (Macherey-Nagel, Hoerdt, France). A transfection
of HEK293F (Thermo Fisher Scientific) suspension cells was
performed with Lipofectamine (FreeStyle MAX Reagent, Thermo
Fisher Scientific), and cells were cultured for five days in
FreeStyle 293 Expression Medium (Thermo Fisher Scientific).
The supernatant was collected, and antibodies were purified on
HiTrap Protein G HP affinity column (GE Healthcare, Buc,
France) with ÄKTA chromatography system.
Surface Plasmon Resonance
Surface plasmon resonance experiments were performed on a
Biacore 3000 instrument at 25◦C using HBS-EP buffer [10 mM
Hepes (pH 7.4), 3 mM EDTA, 150 mM NaCl, and 0.005% (v/v)
non-ionic surfactant P20] (GE Healthcare) as running buffer.
Recombinant Af Crh5 and rCrf2 were immobilized on Fc3 and
Fc2, respectively, of a CM5 sensor chip surface at 300-400 RU
by amine coupling according to the manufacturer’s instructions
(GE Healthcare). Increasing concentrations of scFv, scFv-Fc and
IgG1 were injected 180 s at 50 µL/min on Af Crh5, rCrf2 and
a control flow cell (without the protein) simultaneously. After
following the dissociation for 400 s, surfaces were regenerated by
a short pulse of HCl at 100 mM. All sensorgrams were corrected
by double referencing method and data were globally fitted to
a Langmuir 1:1 or bivalent model using the BIA evaluation
version 4.1.1 software.
Epitope Mapping
Epitope mapping of MS112-IIB1 was performed in peptide array
using an amino-cellulose membrane representing the sequence
of Crf2 in a series of peptides (15mers overlapping by 12 amino
acid residues) (Frank, 2002). After a blocking step in PBS 2%
(w/v) skimmed milk, 0.05% (v/v) Tween 20 for 1.5 h at room
temperature (RT), 40 µg scFv-Fc antibody were incubated in
10 mL PBS 2% (w/v) skimmed milk on the Crf2 membrane
for 2.5 h at RT. After washing with PBS, the bound antibodies
were detected with a secondary goat anti-human IgG antibody
alkaline phosphatase conjugate (Dianova, Hamburg, Germany)
diluted to 1:5,000 and incubated at RT for 1.5 h. Following
two successive washing steps in 0.05% (v/v) Tween 20 PBS
and in citrate-buffered saline (CBS) pH 7.0, staining solution
[10 mL CBS, 1M MgCl2, 40 µL BCIP (Applichem, Darmstadt,
Germany), 60 µL MTT (Sigma-Aldrich, Taufkirchen, Germany)]
was added. The membrane was washed in PBS prior to being
scanned and analyzed.
Localization of identified epitopes was performed on the
Af Crh5 3D structure (Protein Data Bank n◦5NDL) with UCSF
Chimera 1.12 software (Pettersen et al., 2004).
Crf and Crf2 Recombinant Proteins
Af Crh5 recombinant protein was kindly provided by Dr. Daan
Van Aalten at the University of Dundee, United Kingdom
(Fang et al., 2015). rCrf2 recombinant protein was produced as
previously described (Schütte et al., 2009).
Rat Model of Invasive Pulmonary
Aspergillosis
In vivo experiments were performed using a previously described
rat model of IPA (Chandenier et al., 2009). Briefly, male
Sprague-Dawley rats (Janvier Labs, Le Genest-Saint-Isle, France),
6–8 weeks old, 200–225 g, were acclimated in animal facilities
eight days before the beginning of the protocol. At day-5
(day 0 being the date of the infectious challenge), all animals
were immunocompromised intraperitoneally with 75 mg/kg
cyclophosphamide (Baxter, Guyancourt, France), and their food
was changed for a low-protein diet (Safe Diets, Augy, France).
Five-hundred milligrams tetracycline per liter (Sigma-Aldrich,
Saint Quentin Fallavier, France) and 300 mg/L paracetamol
(Sanofi-Aventis, Montrouge, France) were added to their
drinking water to avoid opportunistic infections and limit pain.
A second cyclophosphamide administration of 60 mg/kg was
performed at day-1 to maintain immunosuppression. According
to the protocols, animals were challenged intra-tracheally at
day 0 by aerosolization of 300 µL of a PBS suspension
containing 105 or 106 A. fumigatus conidia with Microsprayer
IA-1B R© (PennCentury, Philadelphia, PA, United States). Rats
were then monitored until the end of the protocol. Regarding
the deleterious clinical signs of aspergillosis, sacrifices were
performed before the end of the protocols if the following criteria
were met: loss of weight ≥ 20%, discomfort score 3 (scored
from 1 to 6 on the basis of appearance changes, e.g., dirty
nose, red-rimmed eyes, ruﬄed fur, extreme pallor; score 1, no
discomfort; score 2, minor discomfort; score 3, poor discomfort;
score 4, serious discomfort; score 5, severe discomfort; score 6,
death), behavior changes (e.g., gasping, wheezing, prostration,
instability) and reaction to stimuli (Morton and Griffiths, 1985).
At the sacrifice, blood, broncho-alveolar lavage fluids and lungs
were collected for subsequent analysis.
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Sequencing of the CRF1 Gene
After culture on Sabouraud gentamicin chloramphenicol agar
plate for 24 h at 35◦C, 80 mg A. fumigatus hyphae were harvested.
Mycelium was disrupted with 0.1 mm glass beads (Ozyme,
Montigny-le-Bretonneux, France) using Cryolys/Precellys 24
(Bertin Instruments, Montigny-le-Bretonneux, France) system in
380 µL of extraction buffer supplied in QIAmp DNA Mini Kit
(Qiagen, Courtaboeuf, France), using two 25 s grinding steps at
6,800 rpm. Subsequent steps were performed accordingly to the
supplier recommendations.
After DNA recovery, an amplification PCR was carried out
using forward primer CCCAGTAGACTCGAGCTAGC and
reverse primer CCCGATGCCGAAATGTATAG (Eurogentec,
Angers, France) specific for CRF1 gene, with an initial
denaturation of 3 min at 94◦C, followed by 35 cycles (30 s at 94◦C,
30 s at 55◦C, 45 s at 72◦C), and a final elongation step of 15 min
at 72◦C. Sequencing was performed using BigDye Terminator
v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific),
with in addition of the primers cited above, the following
supplementary primers: CTTCCTTGACAAAACGCTCC,
CCTGGCACAGGTGTTGTTAG, ACGTCAAGTCCGTCCGT
ATC, and AGCTAGAGCCAGAGCCAGAG. Sanger capillary
electrophoresis was realized with 3130xl Genetic Analyzer
(Applied Biosystems, Villebon-sur-Yvette, France), as
recommended by the supplier instructions. Data were analyzed
using CodonCode Aligner 6.0.2 (CodonCode Corporation,
Centerville, MA, United States) software.
Analysis of the Expression Levels of
CRF1 RNA Variants
Quantification of RNA Levels in vitro
A. fumigatus spores were seeded at 2.37 × 105 per well on
6-well plate in 4 mL of RPMI medium, and were incubated
at 35◦C for 24 h. After removing the medium, the mycelium
was harvested adding 700 µL TRIzol Reagent (Thermo
Fisher Scientific) and grinded with 0.1 mm glass beads
(Ozyme), using Cryolys/Precellys 24 (Bertin Instruments)
system, for two 25 s cycles at 6,500 rpm. The following
RNA isolation steps were performed with RNeasy Plant
Mini Kit (Qiagen) according to the supplier’s instructions.
Recovered RNA was quantified and its integrity was analyzed
by RNA6000 Nano kit (Agilent, Courtaboeuf, France).
Reverse transcription was performed with SuperScript II
Reverse Transcriptase kit (Thermo Fisher Scientific) and
cDNA was quantified by RT-qPCR. Specific primers of
transcripts Crf1 (Forward: GGAACCTACTACCACCGGC,
Reverse: GTGACCGAGCCCTTGATGG), Crf2 (Forward:
CTACTCGGACAACTCTGGCTC, Reverse: ACGGCAGCG
GTAGGTTCC), Asp f9 (Forward: CAAGTCCGTCCGTA
TCGAGA, Reverse: TTTGTTTACGAGGTAGAGCTGG),
and housekeeping gene transcripts gpdA
(glutaraldehyde 3-phosphate dehydrogenase) (Forward:
CACCGTCCACTCCTACACC, Reverse: GCTTGCCGTTGA
GAGAAGG) and TUB1 (β-tubulin) (Forward:
CTTCCAGGTCACCCACTCTC, Reverse: CTGGTGAAC
GGAGAGGGTAG) were used. Amplification was carried out
using the Taqman method, with the following probes: Crf1:
FAM-CAGCAGCAACACCGGCTCTG-BHQ1, Crf2: FAM-AC
CTCCACCCTGGCCACTTC-BHQ1, Asp f9: FAM-ACCTC
CTCCACCACCAGCAC-BHQ1, gpdA: HEX-TGGTCGTACTG
CTGCCCAGAA-BHQ1 and TUB1: CY5-CCGACCGTAT
GATGGCGACCTT-BHQ2. Platinum Quantitative PCR
SuperMix-UDG (Invitrogen) was used to perform the
amplification on LightCycler 480 (Roche, Boulogne-Billancourt,
France) with the following program: decontamination 2′ at 50◦C,
initial denaturation 10′ at 95◦C, first amplification cycle 15′′ at
95◦C and 1′ at 58◦C, second amplification cycle 15′′ at 95◦C
and 1′ at 59◦C, third amplification cycle 15′′ at 95◦C and 1′ at
60◦C, fourth amplification cycle 15′′ at 95◦C and 1′ at 61◦C, fifth
amplification cycle 15′′ at 95◦C and 1′ at 62◦C, followed by 50
cycles 15′′ at 95◦C and 1′ at 63◦C. The cycle threshold values
of each Crf1, Crf2 or Asp f9 transcripts were then compared
to the geometric mean of the cycle threshold values of both
housekeeping genes, allowing the calculation of a ratio and the
assessment of their relative expression.
Quantification of RNA Levels in vivo
Lung tissues from rats infected with 105 conidia of Crf+ strain
were sliced and collected in RNAlater solution (Sigma-Aldrich),
prior to a grinding with GentleMACS (Miltenyi Biotec, Paris,
France) system. After an incubation for 24 h at 4◦C, 25 mg of
tissue were harvested and centrifuged at 3,000 × g for 5 min.
Tissue was then re-suspended in 700µL TRIzol Reagent (Thermo
Fisher Scientific) and RNA extraction and quantitation steps were
performed as previously described for in vitro cultivated strains.
Analysis of the Expression of Crf
Proteins
In vitro Expression by Immunofluorescence
Crf+ strain conidia were seeded at 1.05 × 104 spores per well
in Lab-Tek 8-well chamber slide (Nalge Nunc International,
Villebon-sur-Yvette, France) in 300 µL RMPI medium, and
incubated at 35◦C for 8, 10, 14, or 24 h. At the end of the
incubation, for each well, culture medium was removed and 300
µL ice cold methanol were added for 10 min. A blocking step
was performed using 300 µL of a PBS solution containing 3%
(w/v) BSA (Sigma-Aldrich), 2% (w/v) skimmed milk powder
(Régilait, Macon, France) and 0.05% (v/v) Tween 20 (Thermo
Fisher Scientific) for 10 min. Two hundred microliters of either
scFv-Fc anti-Crf MS112-IIB1 antibody or isotype control diluted
at 2 µg/mL in the previous solution without Tween 20 were
incubated during 1 h at RT. Secondary antibody (anti-human IgG
Alexa Fluor 488, Thermo Fisher Scientific) was added at 1:200
for 1 h at RT. Cell nuclei were stained with 1:1,000 Hoechst
(Interchim, Montluçon, France) solution, before observing the
slide using confocal microscopy (Olympus FV500).
In vitro and in vivo Expression by Western Blot
A. fumigatus spores were seeded in 6-well plates at a density
of 2.37 × 105 spores per well in 4 mL of RPMI medium for
24 h at 35◦C. CWPs extraction was adapted from Pitarch et al.
(2008) protocol. Briefly, culture medium was removed, and wells
were washed with 10 mM Tris-HCl pH 7.4, 5 mM EDTA.
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The fungus was then harvested and suspended in 1 mL of the
previous solution before adding final 2 mM PMSF and 10 µL
inhibitor cocktail (Sigma-Aldrich). The suspension was grinded
with 0.1 mm glass beads (Ozyme), using Cryolys/Precellys 24
(Bertin Instruments) system, for two 25-s cycles at 6,800 rpm.
The cell wall suspension recovered was centrifuged at 1,500 × g
for 10 min and weighed. Three micrograms of cell wall extract
were washed with 5 mL of 50 mM Tris-HCl pH 7.5 solution with
1 mM PMSF. After centrifugation at 1,500 × g for 10 min, cell
wall extracts were incubated at 37◦C for 22 h in 1 mL of the
previous solution containing 1 mM PMSF, 10 mM DTT and 1000
U lyticase (Sigma-Aldrich), under agitation. The suspension was
then centrifuged at 12,000× g for 10 min and the supernatant was
collected. Proteins were precipitated adding 1:10 TCA (Thermo
Fisher Scientific) 100% followed by an incubation in ice for
30 min. After a 10,000× g centrifugation for 15 min, pellets were
washed twice in cold acetone and dried. All samples were frozen
at−80◦C until the Western Blot analysis was performed.
After collection, human BALF samples were centrifuged at
3,000 × g for 10 min. Pellets were re-suspended in 1 mL 10 mM
Tris-HCl pH 7.4, 5 mM EDTA and grinded, as described above.
Lungs of rats infected with 106 conidia were sliced in 25 mg
portions, prior to being re-suspended in 1 mL 10 mM Tris-HCl
pH 7.4, 5 mM EDTA and grinded, as described previously.
Pellets containing precipitated CWPs were re-suspended
in 20 µL of 1X NuPAGE LDS sample buffer (Thermo Fisher
Scientific). Samples were dropped on NuPAGE 10–20%
Tris-Glycine (Thermo Fisher Scientific) electrophoresis
gel, under non-denaturing and non-reductive conditions.
Respectively 0.02 µg and 0.07 µg of recombinant Af Crh5 and
rCrf2 proteins were diluted in the same buffer and deposed
on the gel. Migration was performed in Tris-Glycine-SDS
buffer, and proteins were transferred from the gel to a
PVDF membrane by electrophoretic liquid transfer in Tris-
Glycine buffer. Following a saturation step in Tris-buffered
saline 0.1% (v/v) Tween 20 with 5% (w/v) of skimmed milk
powder (Régilait), primary antibody (scFv-Fc MS112-IIB1)
at 2 µg/mL was incubated on the membrane overnight at
4◦C. Anti-human IgG HRP-coupled secondary antibody
(Jackson ImmunoResearch, West Grove, PA, United States)
was then incubated for 1.5 h at RT. The membrane was
developed using SuperSignal West Pico Chemiluminescent
Substrate (Thermo Fisher Scientific), with a detection on
photographic film.
In vivo Expression by Immunohistochemistry
Lungs of rats infected with Crf+ or Crf- strains were collected
in 4% buffered formaldehyde (VWR, Fontenay-sous-Bois,
France) before changing to ethanol 70% 24 h later. Lungs
were embedded in paraffin before preparing 4 µm slides.
Slides were thereafter rehydrated in successive baths of
xylene and ethanol. Following an antigen retrieval step
in Tris-EDTA pH 9.0 with 0.05% (v/v) Tween 20, an
endogenous peroxidase inactivation step in methanol 5%
(v/v) H2O2 (Sigma-Aldrich) was performed. Blocking was
performed with 5% (v/v) normal goat serum (Sigma-Aldrich)
and 2% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich)
during 1.5 h, before adding primary anti-Crf antibody at
2 µg/mL for 1.5 h. A negative control was carried out in
parallel, incubating primary antibody with recombinant rCrf2
protein. Subsequent steps with secondary biotinylated antibody
and HRP-avidin addition were achieved using Vectastain
ABC kit Human IgG (Vector Laboratories, Peterborough,
United Kingdom), until revelation in DAB (Dako, Les Ulis,
France) and counter-coloration with Gill’s hematoxylin. Slides
were then dehydrated and scanned.
Study of Crf Protein Neutralization
in vitro
Assessment of Crf Deletion Impact on Fungal Growth
Ku80 WT and Ku80 1CRF1 strains conidia were seeded at
3.5 × 104 per well in a 96-well plate, in 200 µL RPMI
medium. Fungal growth kinetics was studied over 48 h by
measuring the 530 nm absorbance every 30 min (Infinite
200 Pro, Tecan, Lyon, France), at 12 different points per
well, to overcome the heterogeneity due to the mycelium
growth. Spectrophotometry method was validated using MTT
method (not shown).
Neutralization of Crf Enzymatic Activity
The assay to measure transglycosylase activity of Crf protein was
carried out as previously described (Mazan et al., 2013). Nine
micrograms of recombinant Af Crh5 protein were pre-incubated
with PBS, IgG1 trastuzumab anti-HER2 antibody (control),
or IgG1 MS112-IIB1 antibody (anti-Crf) in a 2:1 molar ratio
(antibody:Af Crh5) for 30 min at room temperature. A mixture
containing 18 µM sulforhodamine-labeled oligosaccharide
(laminaripentaose L5-SR or chitopentaose CH5-SR) as the
acceptor, and carboxymethyl-chitin (0.1%) as a donor, in
50 mM citrate buffer pH 5.8, was then added to the reaction
in a final volume of 150 µL. Transglycosylation was carried
out at 37◦C and aliquots of 20 µL were taken for each time
point. The reaction was stopped by addition of 20 µL of
40% (v/v) formic acid. Aliquots of 5 µL from the stopped
mixture were spotted in quadruplicates onto a filter paper
and processed as previously described (Mazan et al., 2013).
Enzymatic activity was then determined by a fluorescence
measure (expressed in fluorescence units) in a FLUOStar
Galaxi (BMG Labtech, Ortenberg, Germany) ELISA microplate
reader equipped with a fluorescent detector and filters with an
excitation wavelength of 540 ± 10 nm and emission wavelength
of 570± 10 nm.
Neutralization of Fungal Growth
A. fumigatus spores were seeded at 3.5 × 104 spores per well
in a 96-well plate in 100 µL of RPMI. One hundred microliter,
either of RPMI alone, IgG1 MS112-IIB1 antibody or control
antibody (IgG1 trastuzumab anti-HER2) were then added to
each well, on spores (0 h, no incubation), on germinating spores
(after a 6 h-long incubation at 35◦C) and on 24 h hyphae
(after a 24 h-long incubation at 35◦C). Final concentration
was adjusted in RPMI at 0.5 µg/mL of antibody. Fungal
growth was evaluated after a 48 h incubation at 35◦C, via
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measurements of the absorbance at 530 nm at 12 different
points per well.
Study of Crf Protein Neutralization in vivo
Testing of IgG1 Antibody
Thirty rats were intra-tracheally challenged with 105 A. fumigatus
spores of Crf+ strain and treated extemporaneously with PBS
(n = 6), trastuzumab IgG1 control antibody at 4 mg/kg (n = 12)
or MS112-IIB1 IgG1 anti-Crf antibody at 4 mg/kg (n = 12).
After 32 h, all animals were treated again with intra-tracheal
administration of PBS (control group), 4 mg/kg trastuzumab
(control antibody group) or 4 mg/kg MS112-IIB1 IgG1 (anti-Crf
antibody group), respectively. Seventy-two hours after initial
challenge, all rats were sacrificed and lungs were collected. Lung
tissues were sliced and digested in 9 mL RPMI with 5% (v/v)
fetal bovine serum (FBS) and 125 µg/mL liberase (Roche) for
30 min at 37◦C, using GentleMACS (Miltenyi Biotec) system.
Homogenates were divided in two for fungal load assessment and
study of immune cells recruitment, and centrifuged at 400× g for
5 min at 4◦C.
Assessment of Immune Cell Recruitment by Flow
Cytometry
Homogenate pellets were re-suspended in 4 mL RPMI with 5%
(v/v) FBS and 0.5 mg/mL DNAse (Roche) and incubated with
shaking at 37◦C for 30 min. Following a filtration (100 µm)
step, homogenates were treated with red cells lysing solution
(0.1 mM EDTA, 10 mM KHCO3, 150 mM NH4Cl) during
15 min. Samples were centrifuged at 400 × g, 5 min at 4◦C,
re-suspended in 5 mL PBS 5% (v/v) FBS and filtered again (100
µm). After a final centrifugation step at 400 × g, 5 min at
4◦C, recovered cells were re-suspended in PBS with 5% (v/v)
FBS and 2 mM EDTA (working buffer). For each rat, cells
number was determined with MACS Quant flow cytometer
(Miltenyi Biotec), and four wells of a 96-well round bottom
plate were seeded with 500,000 cells. After centrifugation, 50
µL of working buffer with 0.5% (w/v) mouse anti-rat CD32
(BD Biosciences, Le Pont de Claix, France) were added to
each well and incubated for 15 min. Four antibody mixes
were prepared for the study of immune cell populations in
flow cytometry. To each mix, 1:1,000 Live-dead stain (Thermo
Fisher Scientific) and 0.1 µg mouse anti-CD45 APC-eFluor 780
(Thermo Fisher Scientific) were added. In the neutrophils, total
macrophages, alveolar macrophages and interstitial macrophages
mix, cells were stained with 0.1 µg mouse anti-rat CD11b V450
(BD Biosciences), 1 µg rat anti-rat Ly6G FITC (Abcam, Paris,
France) and 0.2 µg mouse anti-rat CD172a Pe (BioLegend,
London, United Kingdom). In T CD4, T CD8 lymphocytes
and natural killers mix, cells were stained with 0.1 µg mouse
anti-rat αβ T-cell PerCP (BD Biosciences), 0.25 µg mouse
anti-rat CD4 FITC (BD Biosciences), 0.2 µg mouse anti-rat
CD8a V450 (BD Biosciences) and 0.025 µg mouse anti-KLRB1
Pe (Thermo Fisher Scientific). In the B lymphocytes mix,
cells were stained with 0.5 µg mouse anti-rat CD45R FITC
(BD Biosciences) and 0.4 µg mouse anti-rat IgM Pe (BD
Biosciences). In dendritic cells and activated dendritic cells
mix, cells were stained with 0.2 µg mouse anti-rat CD11c
AF647 (AbD Serotec, Kidlington, United Kingdom), 0.5 µg
mouse anti-rat MHC Class II Pe (Bio-Techne, Lille, France)
and 0.5 µg mouse anti-rat CD86 AF405 (Bio-Techne). All
mixes were incubated at 4◦C for 30 min. After centrifugation,
cells were re-suspended in 200 µL working buffer except
neutrophils/macrophages mix in which cell were permeabilized
with BD Cytofix/cytoperm (BD Biosciences), according to
the supplier recommendations. For intramembrane staining of
CD68, 0.1 µg mouse anti-rat CD68 AF647 (AbD Serotec) were
added to this mix and incubated for 25 min at 4◦C. After
centrifugation, cells were re-suspended in 200 µL working buffer.
Cell marker expression was then assessed by flow cytometry
with MACS Quant cytometer (Miltenyi Biotec) and data were
analyzed using VenturiOne 6.0 software (Applied Cytometry,
Dinnington, United Kingdom).
Assessment of in vivo Fungal Load
Twenty-five milligrams of tissue were re-suspended in 80
µL PBS. The suspension was then grinded with 0.1 mm
glass beads (Ozyme) using Cryolys/Precellys 24 (Bertin
Instruments) system, for two 25 s cycles at 6,800 rpm.
Subsequent DNA extraction steps were performed according
to QIAmp DNA Mini Kit (Qiagen) recommendations.
A. fumigatus 28S ribosomal DNA 28S then quantified
by qPCR. Forward primer TCCTCGGTCCAGGCAGG,
reverse primer CTCGGAATGTATCACCTCTCGG, and
probe (FAM-TGTCTTATAGCCGAGGGTGCAATGCG-
BHQ1) were used to perform a Taqman qPCR, with Platinum
Quantitative PCR SuperMix-UDG (Thermo Fisher Scientific)
on LightCycler 480 (Roche) system. In parallel, a calibration
curve was obtained with serial dilutions of DNA (1 × 100
to 1 × 107 fg/µL) from A. fumigatus Crf+ strain cultivated
in vitro. A program with a decontamination of 2′ at 50◦C,
followed by an initial denaturation of 10′ at 95◦C and
50 cycles (15′′ at 95◦C and 1′ at 60◦C) was then used for
the amplification.
Ethics Statement
This study was carried out in accordance with the principles of
the Basel Declaration. The rat model of invasive aspergillosis was
approved by the General Direction for Research and Innovation,
French Ministry of Higher Education and Research through the
accreditation number No. 01901.01, and by the Ethics Committee
for Animal Experimentation of the Val-de-Loire region through
the accreditation number No. C37-261-3.
Collection of human samples was approved by the ethics
committee of CHRU of Tours under research project number
No. 2016-003. No medical intervention relative to this research
protocol was necessary, and the collection of the samples did
not affected patient healthcare. Thus, the ethics committee only
required informed consent of the patients, with no need of
written consent.
Statistical Analysis
Statistical analyses were performed with XLSTAT 2016.02
(Addinsoft, Paris, France) software. Mann–Whitney test was
applied. The α-risk was set to 0.05.
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RESULTS
Anti-Crf2 MS112-IIB1 Antibody Is Able to
Bind to Other Protein Isoforms Coded by
CRF1 Gene
Based on the previous data published by Schütte et al. (2009),
we selected a high affinity single chain fragment variable
(scFv) antibody (MS112-IIB1, high affinity ∼10−10 M) that was
obtained using rCrf2 recombinant protein as immunogen.
Next, the antibody fragment was engineered for therapeutic
purpose, adding a Fc (Fragment crystallizable) part to favor
recruitment of immunity effectors (Supplementary Figure S1).
The affinity of scFv-Fc and IgG1 formats was assessed by surface
plasmon resonance (Figure 1A) for both recombinant rCrf2
protein and a protein (Af Crh5) containing the common sequence
of Crf protein variants (Supplementary Figure S2). ScFv-Fc had
a slightly lower affinity for rCrf2 compared to scFv (1.4 × 10−8
M vs. 8.3 × 10−9 M), while the affinity of IgG1 format was
increased (4.8 × 10−9 M). Moreover, MS112-IIB1 had a higher
affinity for Af Crh5 recombinant protein than for rCrf2, whatever
the antibody format considered, which suggests that MS112-IIB1
binds to an epitope shared by Crf protein variants. To determine
the epitope recognized by MS112-IIB1, we designed 15-mer
overlapping oligopeptides covering the entire sequence of Crf2
protein. We found that MS112-IIB1 binds to two peptide
regions FPQTPMRLRLGS and GPYTMYVKSVRIENA, which
are located in the common sequence of Crf protein variants
(Figure 1B). While the first epitope region was located near
FIGURE 1 | MS112-IIB1 anti-Crf antibody binds to different Crf isoforms. (A) Surface plasmon resonance kinetic analysis of MS112-IIB1 scFv, scFv-Fc, and IgG1
binding to immobilized rCrf2 or AfCrh5 recombinant proteins. Kinetic and affinity constants are summarized in the table. Sensorgrams were fitted globally using a
Langmuir 1:1 model (∗) and bivalent model (∗∗) for scFv and scFv-Fc/IgG1, respectively. An example of sensorgram is displayed for IgG1 and Crf2 (thin lines are the
fitting curves). Rmax: maximum binding level of analyte. Chi2: Chi-square residual value (measure of the average deviation of the experimental data from the fitted
curve; lower Chi2 values indicate a better fit). (B) Epitope mapping of anti-Crf MS112-IIB1 antibody using a peptide array (15mer oligopeptide overlapping, by 12
amino acid residues). Epitope regions were highlighted in bold red (region 1) or green (region 2) on an alignment of Crf1, Crf2, and Asp f9 protein sequences.
Divergent amino acid regions of the three proteins are displayed in blue. Crf2 sequence used for the design of oligopeptides is underlined. (C) Localization of epitope
regions recognized by MS112-IIB1 on AfCrh5 structure. Red: epitope region 1. Green: epitope region 2. Yellow: predicted catalytic site. (D) Study of Crf protein
isoforms recognized by MS112-IIB1 antibody in vitro and in vivo, by Western blot. Cell wall proteins, from A. fumigatus Crf+ or Crf- (natural mutant) strains cultivated
in vitro or inoculated in rats, or from human broncho-alveolar lavage fluid of patient with IPA (IPA BALF), were extracted and analyzed by Western blot, using
MS112-IIB1 antibody at 2 µg/mL. MS112-IIB1 scFv-Fc primary antibody and anti-human IgG secondary antibody were used for the identification of Crf proteins.
Recombinant AfCrh5 and Crf2 (rCrf2) proteins were used as control.
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to the predicted catalytic site of Af Crh5, the second was
located on the opposite side (Figure 1C). Overall, our results
indicate that MS112-IIB1 may be able to recognize all Crf
variants. Accordingly, MS112-IIB1 detected, in Western Blot,
both recombinant Af Crh5 and rCrf2 proteins and several bands
against A. fumigatus cell wall extracts (Figure 1D). The extended
75 kDa band visible in some experiments (Figure 1D) is
probably due to an incomplete digestion of fungal cell wall
by beta-glucanase, in which some sugar residues could be still
bound to proteins (data not shown). The lower bands couldn’t
be related to a specific Crf isoform, due to differences of
migration with recombinant proteins and discrepancies with
regard to the transcription levels (Figure 1D and Supplementary
Figure S2A). Therefore, MS112-IIB1 will be called “anti-Crf
antibody” thereafter throughout the text.
CRF1 Gene Is Highly Conserved in
A. fumigatus Strains
To determine whether Crf proteins and the epitopes targeted by
anti-Crf antibody were conserved to allow its use in a therapeutic
purpose, we sequenced CRF1 gene in 49 isolates of A. fumigatus
recovered from routine clinical practice (Table 1). Overall, 45
strains (92%) showed a 100% conserved sequence of the 1303
nucleotides of CRF1 gene (Supplementary Figure S3). Silent
mutations without an effect on the amino acid sequence were
found in two strains (4%). Three strains (6%) exhibited missense
mutations without affecting epitopes regions recognized by
anti-Crf antibody; among them, one showed three changes in
amino acid sequence. One strain (2%) exhibited a deletion
of two successive nucleotides at the beginning of CRF1 gene
(position 58–59), inducing a frameshift mutation and the
emergence of a Stop codon at amino acid 75 in all Crf
proteins (referred to as “Crf-” strain). All 49 strains studied
(100%) shared the same mutation in nucleotide position 1110,
when compared with the published sequence of Af293 strain
(NCBI accession number NC_007194), with the replacement
of a cytosine (Af293) for a guanine (other strains), inducing
a missense mutation (replacement of a threonine by a serine
residue) (Supplementary Figure S3). All the mutations did
not affect epitope regions recognized by anti-Crf antibody,
therefore allowing it to bind to CRF1 gene products in different
pathophysiological conditions, when they are expressed.
Crf Protein Is Expressed in vitro and
in vivo, in Different Pathophysiological
Conditions
To study the expression of CRF1 gene, we designed primers to
specifically detect each CRF1 alternative transcripts (encoding
Crf1, Crf2, and Asp f9) and assessed their quantitative
expression by RT-qPCR (Figure 2A). As shown for the reference
A. fumigatus strain Crf+ (Figure 2B), Asp f9 was the most
expressed transcript; Crf1 RNA expression was lower by about
103-fold than for Asp f9 and Crf2 was the less expressed transcript
with a difference of 105-fold compared with Asp f9. The RNA
expression profile of Crf1, Crf2 and Asp f9 transcripts isolated
from IPA patients (n = 2), ABPA patients (n = 2) or CF colonized
patients (n = 2) was similar to Crf+ strain (Figure 3A).
Next, we studied CRF1 gene expression at the protein level.
The strains (n = 6) exhibited a similar profile than Crf+ strain
in Western blot (data not shown), and we detected Crf proteins
in 98% of A. fumigatus clinical isolates (n = 48) – except
for Crf- strain – as shown by immunofluorescence (Table 1).
Kinetics indicated that Crf proteins began to be detectable
after 8 h incubation with growing conidia (Figure 3B).
Expression was initially localized in budding, and then in
fungal cell wall, and in septa when they began to develop
at around 14 h growth. Location of Crf proteins was
similar in all A. fumigatus clinical isolates, except Crf- strain
(data not shown).
As in vitro growth is not representative of in vivo conditions
(Hartmann et al., 2011), we then assessed the expression of Crf+
strain CRF1 RNA transcripts in a rat model of aspergillosis.
In vivo, we highlighted a difference of expression of Crf1 and
Crf2 transcripts vs. in vitro (Figure 3C). While the expression
of the former was increased by 34-fold in vivo, the latter was
not detected in vivo. Expression of Asp f9 was similar in both
FIGURE 2 | Expression of CRF1 alternative transcripts in A. fumigatus. (A) Schematic representation of CRF1 gene and the three mRNA transcripts, Crf1, Crf2, and
Asp f9 with the corresponding primers used for amplification. Nucleotide positions of the beginning/end of each exon (boxes) and intron (Int., in full lines) are
mentioned under the gene and the transcripts. Non-coding regions are identified in dotted lines. SP: position of predicted signal peptide. CS: position of predicted
catalytic site. GPI: position of predicted GPI anchor. Position of primers used for the amplification of the different transcripts is indicated by gray arrows (>).
(B) In vitro expression of Crf1, Crf2 and Asp f9 RNA transcripts in RT-qPCR. Transcript expression was analyzed in Crf positive strain by RT-qPCR and normalized
toward gpdA (glutaraldehyde 3-phosphate dehydrogenase) and TUB1 (beta-tubulin) housekeeping genes, set to 1. Results (n = 5) are expressed in mean ± SD.
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FIGURE 3 | Expression of Crf transcripts and isoforms in clinical strains, in vitro and in vivo. (A) CRF1 RNA transcript expression in different clinical strains, by
RT-qPCR. Results were normalized toward gpdA and TUB1 housekeeping genes, set to 1. Results are expressed in mean ± SD. IPA, strains from patients with
invasive pulmonary aspergillosis (including Crf+); ABPA, strains from patients with allergic bronchopulmonary aspergillosis; CF, strains from patients with colonization
(cystic fibrosis); Crf-, clinical strain with natural frameshift mutation, with no expression of Crf proteins. (B) Expression kinetic and localization of Crf proteins (in green)
in vitro by immunofluorescence in confocal microscopy. MS112-IIB1 scFv-Fc anti-Crf antibody (or isotype) at 2 µg/mL were used. Cell nuclei were stained in
Hoechst (in blue). Scale bar: 50 µm or 10 µm. Original magnification: ×400. (C) Differential expression of CRF1 RNA transcript in vivo and in vitro, by RT-qPCR.
RNAs were extracted Crf+ strain cultured in vitro or from lungs of rats infected by Crf+ strain. Results (n = 5) are expressed in mean ± SD. (D) Expression of Crf
proteins (in brown) in vivo, in rat lungs tissues, by immunohistochemistry. Slides of rat lungs either infected by Crf+ or Crf- (natural mutant) strain were studied with
MS112-IIB1 scFv-Fc antibody at 2 µg/mL or control. One slide was treated in HES coloration. Scale bar: 50 µm. Magnification: ×400.
conditions. We confirmed the expression of Crf proteins in
the rat model by Western blot, which also showed a different
profile than in vitro (Figure 1D). Mass differences may be
attributed to posttranslational modifications (i.e., glycosylations),
as previously described (Leach and Brown, 2012) and predicted
for Crf proteins in silico (not shown). We then studied the
in vivo expression of Crf proteins in the lungs of infected
rats by immunohistochemistry. Crf+ strain exhibited a specific
signal located in areas of fungal growth, on the periphery
of infectious foci, where hyphae invade surrounding tissues
(Figure 3D). Moreover, the expression of Crf proteins in
lung tissues from a patient with IPA was also observed by
immunohistochemistry (Supplementary Figure S4). Finally, the
study of the expression of Crf proteins in broncho-alveolar
lavage fluid collected from a patient suffering of IPA exhibited
a similar profile to the profile observed in the rat model
of IPA (Figure 1D).
Deletion of CRF1 Gene Reduces
A. fumigatus Growth
To characterize the role of Crf proteins on the fungal growth
we used a knock-out mutant deleted for CRF1 gene, named
1CRF1 (Supplementary Figure S5). A growth study revealed a
slower growth over time for mutant compared to wild type strain,
with a difference visible from 15 h incubation (Figure 4A). At
48 h, mutant growth was significantly altered (p < 0.001) with a
decrease by 23.6% (Figure 4B).
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TABLE 1 | Sequencing of CRF1 gene on clinical strains of Aspergillus fumigatus and assessment of Crf expression by immunofluorescence.
Mutation type Proportion of
strains
Strain
name
Detail of mutated strains IF positive
strains
Nucleotide changes Amino acid changes
None (conserved) 45/49 (92%) Crf+ / / 45
IPA 2
ABPA 2
CF 2
Silent mutation 2/49 (4%)∗ Mutation in position 190 (C→T) Silent mutation in codon 43 2∗
Mutation in position 1138 (C→T) Silent mutation in codon 341
Missense mutation 3/49 (6%)∗ ABPA 1 Mutation in position 629 (G→T) Amino acid change in codon 172 (Val→Phe) 3∗
Mutation in position 927 (T→C) Amino acid change in codon 271 (Ile→Thr)
CF 1 Mutation in position 927 (T→C) Amino acid change in codon 271 (Ile→Thr)
Mutation in position 1124 (A→T) Amino acid change in codon 337 (Thr→Ser)
Mutation in position 1126 (C→T)
Frameshift mutation 1/49 (2%) Crf- Deletions in positions 58-59 Open reading frame shift 0
Change of all amino acids from codon 20
Stop codon emergence in codon 75
Forty-nine isolates of A. fumigatus were collected at the CHRU of Tours (France), from respiratory samples of patients without development of aspergillary disease (n = 38),
or affected by ABPA (n = 4), invasive pulmonary aspergillosis (n = 3), aspergilloma (n = 1), Aspergillus bronchitis (n = 1), or from environmental contamination (n = 2).
Groups indicated with (∗) contain a common strain that cumulates silent and missense mutations. IF, Immunofluorescence.
FIGURE 4 | Growth of CRF1 engineered mutant strain in vitro. (A) Assessment of the consequences of the absence of CRF1 gene (coding Crf1, Crf2, and Asp f9
proteins) on fungal growth. A growth kinetic was realized on Ku80 and Ku80 1CRF1 strains with a reading of 530 nm absorbance every 30 min, during 48 h.
(B) Growth differences at 48 h. Results (n = 15) are expressed in mean ± SEM; Mann–Whitney statistical test was used. ∗∗∗p < 0.001.
Anti-Crf Antibody Neutralizes Enzymatic
Activity of Crf and Reduces Fungal
Growth in vitro
Given the involvement of CRF1 gene in A. fumigatus growth,
we investigated whether anti-Crf IgG1 antibody may neutralize
Af Crh5 protein enzymatic activity and decrease fungal growth
in vitro. Using a fluorescence in vitro enzymatic assay (Mazan
et al., 2013), the transglycosylase activity of Af Crh5 protein was
measured using sulforhodamine (SR)-labeled oligosaccharides
derived from β-1,3 glucan (L5-SR) and chitin (CH5-SR) as
acceptors and carboxymethyl-chitin (CM-chitin) as donor.
Af Crh5 showed transglycosylation activity with both substrates
(Figure 5A). Moreover, when compared to an unrelated control
antibody (trastuzumab), the anti Crf antibody exhibited a
complete inhibition of the transglycosylase activity with both
acceptors (Figure 5A). In addition, antibody recognized epitopes
have been shown to be very close to the predicted catalytic site of
Crf protein (Figure 1C).
Anti-Crf antibody was then tested in vitro on A. fumigatus
cultures (Figure 5B) of spores (0 h growth), germinating
spores (6 h growth) and hyphae (24 h growth). Compared
to irrelevant antibody (control isotype trastuzumab), after a
48 h-long culture, anti-Crf IgG1 antibody elicited a decreased
growth of 12.3% (p< 0.001) when added onto 0 h spores, but with
no visible structural change to microscopic observation. Growth
difference was observable from 15 h incubation (Supplementary
Figure S6A). No neutralization effect was observed when
anti-Crf was added on 6 h germinating spores or 24 h
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FIGURE 5 | Neutralization of Crf proteins in vitro, by enzymatic assay and fungal growth inhibition assay. (A) Neutralization of recombinant Crf enzymatic activity by
anti-Crf IgG1 antibody. The rates of transglycosylation catalyzed by AfCrh5 recombinant protein were determined using 18 µM sulforhodamine-labeled
oligosaccharides (laminaripentaose L5-SR or chitopentaose CH5-SR) as acceptor and carboxymethyl-chitin (0.1%) as a donor in 50 mM citrate buffer pH 5.8.
AfCrh5 was pre-incubated in PBS (No antibody), IgG1 trastuzumab anti-HER2 antibody (Control antibody), or IgG1 MS112-IIB1 antibody (Anti-Crf antibody) at 2:1
(antibody:AfCrh5) molar ratio. Data represent the media and standard deviation of at least three independent experiments. F. U., arbitrary fluorescence units.
(B) Neutralizing effects of anti-Crf IgG1 antibody on fungal growth. Anti-Crf IgG1 antibody or control antibody were added on Crf+ strain fungal cultures of 0 h, 6 h or
24 h, at a final concentration of 0.5 µg/mL. Absorbance at 530 nm was read after a 48 h incubation. Results (n = 16) are expressed in mean ± SEM; Mann–Whitney
statistical test was used. ∗∗∗p < 0.001.
hyphae, suggesting that Crf inhibition is not sufficient to block
A. fumigatus growth. Studies with scFv-Fc antibody format gave
similar results (Supplementary Figure S6B).
Treatment With Anti-Crf Antibody
Stimulates the Recruitment of Immune
Cells in vivo but Does Not Inhibit Fungus
Growth
Because anti-Crf antibody (IgG1 format) contained a Fc domain
that may favor the recruitment of immune effectors and help to
eliminate the fungus, we then examined the effects of anti-Crf
antibody in a rat model of aspergillosis.
First, we investigated immune cell recruitment in the lungs
by flow cytometry (Figure 6A and Supplementary Figure S7A).
Animals treated with anti-Crf IgG1 antibody showed a significant
increase in the recruitment of neutrophils (increase by 59%
compared to PBS, p < 0.05), total macrophages (increase by 23%
compared to PBS, p < 0.05), alveolar macrophages (increase by
134% compared to PBS, 63% compared to irrelevant antibody,
p < 0.001) and T CD4 lymphocytes (increase by 42% compared
to PBS, p < 0.05) compared to the control groups (PBS
and irrelevant control antibody trastuzumab). The other cell
populations remained unchanged.
However, at the time of sacrifice, no difference was observed
in the lung fungal load between PBS group (1.0 × 102 fg/µL),
irrelevant antibody group (9.5 × 102 fg/µL) and anti-Crf IgG1
antibody group (2.3 × 102 fg/µL) (Figure 6B). Testing of
scFv-Fc antibody format gave similar results (Supplementary
Figure S7B). There was no statistical difference regarding overall
survival between control groups (aerosolized intra-tracheally
with either PBS or irrelevant control antibody) and treated group
(treated with anti-Crf scFv-Fc antibody). Survival time in all
groups did not exceed 120 h post-infection.
DISCUSSION
Aspergillus fumigatus is an environmental mold fungus which is
responsible for invasive aspergillosis, a life-threatening infection
that is usually encountered in immunocompromised hosts.
Current treatments against aspergillosis suffer from either limited
efficacy or deleterious side effects, or both, which therefore
restricts their use. While several antibodies have been raised
against this fungus for a diagnostic purpose, only a few have
been developed for therapeutic applications (Chaturvedi et al.,
2005, 2009; Schubert et al., 2018). Therapeutic antibodies are
emerging as a new class of anti-infectious agents and may
be suited for treatment against A. fumigatus (Kuhn et al.,
2016; Sécher et al., 2018; Wagner and Maynard, 2018). Usually,
therapeutic antibodies target highly immunogenic antigens that
are expressed on the cell surface. Herein, we assessed the
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FIGURE 6 | Anti-Crf IgG1 antibody effects in a rat model of IPA. Neutropenic rats were infected by 105 spores of Crf+ strain, and challenged extemporaneously
either with intra-tracheal aerosolization of PBS (n = 6), control antibody (Control Ab, n = 12) or anti-Crf IgG1 antibody (n = 12). Antibody were administered twice
(4 mg/kg), with the spores and 32 h post-infection. Rats were sacrificed 72 h after the infection. (A) Evaluation of IgG1 effects on the recruitment of immune cells on
infected rat lungs. Immune cells were extracted from lungs and processed in flow cytometry. Neutrophils (CD11bhi, Ly6Ghi), total macrophages (CD11bhi, Ly6Glow),
alveolar macrophages (CD11bhi, Ly6Glow, CD172hi, CD68hi), interstitial macrophages (CD11bhi, Ly6Glow, CD172low, CD68hi), T CD4 lymphocytes (CD4+, TCR+), T
CD8 lymphocytes (CD8a+, TCR+), B lymphocytes (CD45R+, IgM+), natural killers (KLRB1+), dendritic cells (CD11chi, MHC-IIhi) and activated dendritic cells
(CD11chi, MHC-IIhi, CD86hi) populations were studied. Results are expressed in median ± interquartile (box) with min/max (bars); Mann–Whitney statistical test was
used. ∗p < 0.05, ∗∗∗p < 0.001. (B) Evaluation of IgG1 effects on the lung fungal load of a rat model of IPA. Fungal DNA was extracted from lungs and A. fumigatus
load was assessed by assaying 28S ribosomal DNA by qPCR. Results are expressed in mean ± SD; Mann–Whitney statistical test was used.
relevance of Crf CWPs, which have been known for years to be
allergens and have been quite successfully used in vaccination
assays (even considering the limitation of immunocompromised
context), as molecular targets for antibodies to treat aspergillosis
(Ramadan et al., 2005; Medici and Poeta, 2015). According to
our results discussed below, Crf proteins and anti-Crf antibodies
display several benefits and fulfill several requirements for the
development of anti-infectious therapeutic strategy.
Firstly, our findings indicate that Crf proteins are suitable
molecular targets for antibody-based therapy because of the high
conservation of CRF1 gene within A. fumigatus specie. If less
than 10% of the studied clinical strains exhibited mutations,
most of them had a limited impact on protein expression; only
one isolate showed a mutation resulting in an early codon
stop in CRF1 gene (Crf-mutation). Secondly, Crf proteins are
highly and constantly expressed. The in vitro study by RT-qPCR
and Western blotting successfully highlighted the homogenous
production of Crf transcripts, whatever the clinical origin of
the tested strains. Whereas Asp f9 was strongly expressed, Crf2
expression was found to be very low, therefore it can explain
why this transcript has not been identified so far in many
previous works. In the rat model of IPA, Crf1 and Asp f9
were also found to be expressed at a high level by RT-qPCR.
Unfortunately, Crf1, Crf2 and Asp f9 isoforms could not be
linked to the bands observed in the Western blot, because of
inconsistencies in molecular weights and previously described
transcription levels; use of mass spectrometry should allow their
identification. Crf proteins were expressed on germinating spores
and hyphae of A. fumigatus, the latter being the representative
stage of clinical aspergillosis. As for the in vitro experimentations,
in vivo localization of Crf proteins was found to be heterogeneous
but maximal in the regions of fungal growth, at the surface of
buddings and septa areas (Arroyo et al., 2007; Schütte et al.,
2009). Crf proteins were mostly expressed in the periphery of
infectious foci, which is consistent with the fact that the fungus
is more metabolically active at these sites (Willger et al., 2009).
Infectious foci usually grow from the center to the outer region,
theoretically thus enabling easy access to therapeutic antibodies,
independently of the route of administration. At last, Crf proteins
were proven to play a structural role in A. fumigatus growth.
Indeed, engineered knock-out mutant for CRF1 gene (1CRF1)
exhibited a significant but modest decrease in fungal growth,
visible after a 15 h-culture. This finding may be due to a loss of
A. fumigatus cell wall integrity, knowing the suspected action of
Crf in the linkage of chitin to β(1-3)glucans. The relative limited
impact of Crf proteins in A. fumigatus growth may be attributed
to a compensation by ortholog proteins with the same function
(Crh1, Crh2, Crh3, and Crh4) or overproduction of other cell
wall components (Arroyo et al., 2016). All the aforementioned
reasons led us to consider Crf proteins as relevant antigens
for anti-Crf therapeutic antibodies. However, engineering of
anti-Crf fragment antibodies (with only antigen binding site)
in full-length antibodies would be required to optimize their
anti-fungal activity, mediating effector functions through the
Fc domain, as previously demonstrated for other therapeutic
antibodies (Maloney et al., 2002; Mayr et al., 2017).
In addition, we demonstrated in silico, in vitro, and in vivo
that anti-Crf antibodies display several advantages and may
be used in A. fumigatus infection. First, anti-Crf antibodies
are highly specific. As previously shown by Schütte et al. (2009)
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and based on sequence alignments of Crf proteins (data not
shown), it is most likely that anti-Crf antibodies would not
exhibit cross reactivity toward other Aspergillus species or against
yeasts like Candida albicans (Schütte et al., 2009). Moreover,
anti-Crf antibodies did not show cross reactivity against known
Crf orthologs Crh1, Crh2, Crh3, and Crh4, as demonstrated
by the absence of unspecific bands in the Western blot for
the engineered mutant of Crf. Finally, anti-Crf-antibody did
not show off-target binding, but they showed a high affinity,
which increased after the format modification from scFv
into IgG1. Epitope mapping indicated that anti-Crf antibodies
recognize the distinct Crf isoforms encoded by CRF1 gene,
since epitope regions were found to be located in the common
regions for Crf1, Crf2 and Asp f9; this was supported by
Western blotting and surface plasmon resonance. We also
demonstrated the neutralizing property of anti-Crf antibodies,
as demonstrated by their capacity to inhibit the enzymatic
activity of a recombinant Af Crh5 protein. This is consistent
with the location of the first epitope region (epitope 1), which
was very close to the predicted catalytic site of epitopes in
the Af Crh5 structure. To date, there is insufficient information
to determine whether the antibodies neutralize Crf enzymatic
activity through steric hindrance or through induction of a
conformational modification of the protein structure, which is
a possibility for the second epitope region (epitope 2). In light
of these initial results, anti-Crf antibodies were then tested
in vitro on fungal cultures. Unfortunately, they only enabled
partial inhibition of fungal growth when added to a spore
suspension, but had no action against germinating spores or
hyphae. Despite the fact that Crf proteins were sometimes found
secreted (Wartenberg et al., 2011), it is unlikely that the limited
effect of anti-Crf antibodies might be due to sequestration by
soluble Crf since increasing the amount of antibody did not result
in a higher inhibitory effect, in vitro (not shown). Considering
the expression kinetics of Crf, a very early therapeutic action
is probably required in order to act efficiently on the fungus
growth. Administration of the antibodies at 0 h could allow
early neutralization of Crf proteins, as soon as they are expressed
at the beginning of the germination. Considering the limited
inhibition of anti-Crf antibody in vitro – associated to its Fab
part only –, we tested full-length anti-Crf antibody activity in
a rat model of IPA. We revealed the ability of their Fc part to
recruit immune cells in vivo, with the significant demonstration
of a major and increased recruitment of neutrophils, total
macrophages and alveolar macrophages. As neutrophils and
macrophages are the first defense barrier against A. fumigatus
(Dagenais and Keller, 2009), their recruitment, could take
place via ADCC (antibody dependent cell-mediated cytotoxicity)
or ADCP (antibody dependent cell-mediated phagocytosis)
mechanisms, thus suggesting that anti-Crf antibodies are able
to stimulate the most important components of the natural
immune response during aspergillosis. Even if the adaptive
response is quite limited in IPA, increased stimulation of the
CD4+ T-lymphocytes population at time of the sacrifice (72 h)
is consistent with the usual kinetics of recruitment of such
cells during natural recovery from infection (Bozza et al.,
2002; Rivera et al., 2005). Local attraction of CD4+ T-cells in
infected lungs could have led to the reinforcement of neutrophils
and macrophage recruitment with the production of cytokines
and chemokines. Surprisingly, no significant differences were
observed in the recruitment of dendritic cells (including
activated), even though these cells (among other subsets) are
known to be at the origin of CD4+ T-cells activation in
lymphoid nodes through antigen presentation process (Rivera
and Pamer, 2009), inducing either a Th1 (protective), Th2
(deleterious) or Th17 (still controversial) differentiation profile
(Dewi et al., 2017). Noteworthy, the therapeutic effect of
anti-Crf antibodies was insufficient to decrease the fungal burden
in our rat model of IPA and to improve significantly the
overall survival.
Although Crf proteins and anti-Crf antibodies meet most
of the criteria for an ideal antigen target and ideal therapeutic
antibodies, antifungal impact was not sufficient to efficiently
inhibit fungal growth in vivo. Such a strategy is, however,
relevant, as shown by previous studies where in vivo testing
of IgG or IgM against CWPs demonstrated a decrease in
fungal burden, which was consistent with a therapeutic effect
(Chaturvedi et al., 2005, 2009). The limited effect of anti-
Crf antibodies may be due to several parameters: first, the
rat model of IPA we used to assess the effects of anti-
Crf antibodies in vivo (Chandenier et al., 2009). Given IPA
epidemiology, we selected a neutropenic model rather than a
steroid treated model. Neutropenia context represents more than
50% of clinical cases, including patients with acute leukemia and
chronic lymphoproliferative disorders for which the mortality
rate is the higher (Lortholary et al., 2013). However, in spite
of its high reproducibility, the animal model may be quite
questionable because it usually leads rapidly to death within 2–
4 days after the infectious challenge. One can suspect that this
time-lapse was too short to thoroughly assess the therapeutic
effects of anti-Crf antibodies (Desoubeaux and Cray, 2017).
Another hypothesis has been raised concerning the antibody
engineering: even if human IgG1 has been described to interact
with rat Fc gamma receptor of rat macrophages (Boltz-Nitulescu
et al., 1981) – which we confirmed in this study by the
ability of our anti-Crf antibodies to recruit several populations
of immune cells –, this interaction may be insufficient to
prevent the development of the infection. In such a case,
further engineering of the Fc part (modulation of fucosylation,
galactosylation. . .) would allow an enhanced interaction (Shields
et al., 2002; Thomann et al., 2016). In contrast, no one can
argue that the antibody doses used in this study were too low:
whereas Chaturvedi et al. (2005) used a mouse model treated
with the rat equivalent of 2.5 mg/kg (Nair and Jacob, 2016)
in intravenous single dose to demonstrate the anti-Aspergillus
activity of their Mab A9 antibody, we used two repeated doses
of 4 mg/kg, administrated in situ, directly into the airways
(Chaturvedi et al., 2005). Local delivery of antibodies through
the airways was probably the optimal route to achieve a high
concentration of the macromolecule within the lungs, where
the fungus is primarily located (Guilleminault et al., 2014;
Respaud et al., 2015).
Finally, we can hypothesize that Crf proteins themselves
can be the cause of the moderate antifungal activity of the
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anti-Crf antibodies. The lack of Crf proteins did not result
in a totally non-viable phenotype, and we found only
a slight – but significant – decrease of fungal growth
with the mutant deleted for the CRF1 gene. Surprisingly,
previous studies on CRF1 mutants did not reveal changes
in fungal growth, possibly due to different experimental
conditions [Chabane S, Reichard U, unpublished; Fang W,
Van Aalten DM, unpublished (Fang et al., 2015)]. These
results were also confirmed by the in vitro targeting of
Crf proteins by our antibodies, which only exhibited a
limited growth decrease. During our investigations, we also
discovered a natural mutant for the expression of Crf proteins
(Crf-) in a clinical strain which did not display obvious
phenotypic changes in fungal morphology and growth. Thus,
a compensation of Crf activity by an overexpression of
other orthologous transglycosylases like Crh1, Crh2, Crh3,
and Crh4 is probable, allowing the fungus to keep growing
(Arroyo et al., 2016). Thus, combination of antibodies targeting
different CWPs of A. fumigatus may be relevant to avoid
compensatory mechanisms.
Overall, this study demonstrated that Crf transglycosylases
are a theoretically relevant target for therapeutic antibodies,
because they are ubiquitously expressed by Aspergillus fumigatus
molds. Use of anti-Crf antibodies, initially developed for
a diagnosis purpose against Crf2 protein, did not only
exhibit recognition of several Crf isoforms, but also a
neutralizing activity against all these enzymes. However,
their antifungal effects on fungal growth were moderate,
limiting their use for a therapeutic purpose if considered
alone. Combination of antibodies with anti-infectious agents
may be an attractive strategy as it may lead to a synergistic
effect (Al-Hamad et al., 2011; Song et al., 2012), but the
interest of associating antibody and antifungal drugs remains
to be clearly demonstrated (Richie et al., 2012; Bugli et al.,
2013). Cocktail of antibodies targeting several proteins
involved in the cell wall construction (as β(1-3)glucans or
chitin synthesis enzymes) may avoid escape mechanisms
and furnish a less toxic combination therapy to classic
chemical molecules in the treatment of IPA. Overall our
findings offer future perspective for the design of new
anti-Aspergillus therapeutics.
AUTHOR CONTRIBUTIONS
DC, MH, JA, JC, NH-V, and GD designed the experiments. DC,
MS, AS, AC, CP, GM, MP, PM, NH-V, and GD performed the
experiments. DC, JC, NH-V, and GD wrote the manuscript.
FUNDING
This work has been funded with support by LabEx
MAbImprove (French National Research Agency under the
program “Investissements d’avenir” Grant Agreement LabEx
MAbImprove: ANR-10-LABX-53-01) grant, and Inserm
Transfert (French National Institute of Health and Medical
Research) CoPoC CRFung grant.
ACKNOWLEDGMENTS
The authors would like to thank LabEx MAbImprove
(French National Research Agency under the program
“Investissements d’avenir” Grant Agreement LabEx
MAbImprove: ANR-10-LABX-53) for the support of this
work. They are grateful to the staff of the Parasitology –
Mycology – Tropical Medicine Laboratory and Damien Sizaret
of anatomopathology laboratory in the CHRU of Tours for their
support and for providing biological samples. They thank Wenxia
Fang from the Centre for Gene Regulation and Expression,
University of Dundee, United Kingdom, for kindly giving
them access to Ku80 and 1CRF1 strains, and recombinant Crf
protein. They finally thank Émilie Dalloneau for assistance on
flow cytometry experiments, Saskia Helmsing and Mathilde
Saccas for technical assistance, and the staff of animal facilities
PST Animaleries.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2019.00600/full#supplementary-material
REFERENCES
Al-Hamad, A., Burnie, J., and Upton, M. (2011). Enhancement of antibiotic
susceptibility of Stenotrophomonas maltophilia using a polyclonal antibody
developed against an ABC multidrug eﬄux pump. Can. J. Microbiol. 57,
820–828. doi: 10.1139/w11-076
Arroyo, J., Farkaš, V., Sanz, A. B., and Cabib, E. (2016). ‘Strengthening the
fungal cell wall through chitin–glucan cross-links: effects on morphogenesis
and cell integrity’. Cell. Microbiol. 18, 1239–1250. doi: 10.1111/cmi.
12615
Arroyo, J., Sarfati, J., Baixench, M. T., Ragni, E., Guillén, M., Rodriguez-Peña, J. M.,
et al. (2007). The GPI-anchored Gas and Crh families are fungal antigens. Yeast
24, 289–296. doi: 10.1002/yea.1480
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P., et al.
(2014). Population-based analysis of invasive fungal infections. Emerg. Infect.
Dis. 20, 1149–1155. doi: 10.3201/eid2007.140087
Boltz-Nitulescu, G., Bazin, H., and Spiegelberg, H. L. (1981). Specificity of fc
receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages. J. Exp. Med. 154,
374–384. doi: 10.1084/jem.154.2.374
Bozza, S., Gaziano, R., Spreca, A., Bacci, A., Montagnoli, C., di Francesco, P., et al.
(2002). Dendritic cells transport conidia and hyphae of Aspergillus fumigatus
from the airways to the draining lymph nodes and initiate disparate Th
responses to the fungus. J. Immunol. 168, 1362–1371. doi: 10.4049/jimmunol.
168.3.1362
Bugli, F., Cacaci, M., Martini, C., Torelli, R., Posteraro, B., Sanguinetti, M.,
et al. (2013). Human monoclonal antibody-based therapy in the treatment
of invasive candidiasis. Clin. Dev. Immunol. 2013:403121. doi: 10.1155/2013/
403121
Cabib, E. (2009). Two novel techniques for determination of polysaccharide cross-
links show that Crh1p and Crh2p attach chitin to both Beta(1-6) - and Beta(1-3)
glucan in the Saccharomyces cerevisiae cell wall. Eukaryot. Cell 8, 1626–1636.
doi: 10.1128/EC.00228-09
Frontiers in Microbiology | www.frontiersin.org 14 March 2019 | Volume 10 | Article 600
fmicb-10-00600 March 22, 2019 Time: 17:56 # 15
Chauvin et al. Anti-Crf Antibodies for Targeting Aspergillus fumigatus
Chandenier, J., Bernard, S., Montharu, J., Bailly, E., Fetissof, F., De Monte, M., et al.
(2009). The utility of a nebulised intra-tracheal rat model of invasive pulmonary
aspergillosis. Mycoses 52, 239–245. doi: 10.1111/j.1439-0507.2009.01695.x
Chaturvedi, A. K., Kavishwar, A., Shiva Keshava, G. B., and Shukla, P. K. (2005).
Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall
glycoprotein protects against experimental murine aspergillosis. Clin. Vaccine
Immunol. 12, 1063–1068. doi: 10.1128/CDLI.12.9.1063-1068.2005
Chaturvedi, A. K., Kumar, R., Kumar, A., and Shukla, P. K. (2009). A monoclonal
IgM directed against immunodominant catalase B of cell wall of Aspergillus
fumigatus exerts anti-A. fumigatus activities. Mycoses 52, 524–533. doi: 10.1111/
j.1439-0507.2008.01635.x
Crameri, R., and Blaser, K. (1996). Cloning Aspergillus fumigatus allergens by
the pJuFo filamentous phage display system. Int. Arch. Allergy Immunol. 110,
41–45. doi: 10.1159/000237308
Da Silva Ferreira, M. E., Kress, M. R. V. Z., Savoldi, M., Goldman, M. H. S.,
Härtl, A., Heinekamp, T., et al. (2006). The akuBKU80 mutant deficient for
nonhomologous end joining is a powerful tool for analyzing pathogenicity in
Aspergillus fumigatus. Eukaryot. Cell 5, 207–211. doi: 10.1128/EC.5.1.207-211.
2006
Dagenais, T. R. T., and Keller, N. P. (2009). Pathogenesis of Aspergillus fumigatus
in invasive aspergillosis. Clin. Microbiol. Rev. 22, 447–465. doi: 10.1128/CMR.
00055-08
D’Enfert, C. (1996). Selection of multiple disruption events in Aspergillus fumigatus
using the orotidine-5’-decarboxylase gene, pyrG, as a unique transformation
marker. Curr. Genet. 30, 76–82. doi: 10.1007/s002940050103
Desoubeaux, G., Bailly, É, and Chandenier, J. (2014). Diagnosis of invasive
pulmonary aspergillosis: updates and recommendations. Méd. Mal. Infect. 44,
89–101. doi: 10.1016/j.medmal.2013.11.006
Desoubeaux, G., and Cray, C. (2017). Rodent models of invasive aspergillosis due to
Aspergillus fumigatus: still a long path toward standardization. Front. Microbiol.
8:841. doi: 10.3389/fmicb.2017.00841
Dewi, I., van de Veerdonk, F., and Gresnigt, M. (2017). The multifaceted role of
T-helper responses in host defense against Aspergillus fumigatus. J. Fungi 3:55.
doi: 10.3390/jof3040055
Engler, C., Kandzia, R., and Marillonnet, S. (2008). A one pot, one step, precision
cloning method with high throughput capability. PLoS One 3:e3647. doi: 10.
1371/journal.pone.0003647
Fang, W., Beau, R., Latgé, J. P., Sanz, A. B., Arroyo, J., and Van Aalten, D. (2015).
“Cross-linking is required for cell wall assembly in Aspergillus fumigatus,” in
Proceedings of the 2015 Cell Wall Meeting (Paris: Institut Pasteur).
Frank, R. (2002). The SPOT-synthesis technique: synthetic peptide arrays on
membrane supports - principles and applications. J. Immunol. Methods 267,
13–26. doi: 10.1016/S0022-1759(02)00137-0
Guilleminault, L., Azzopardi, N., Arnoult, C., Sobilo, J., Hervé, V., Montharu, J.,
et al. (2014). Fate of inhaled monoclonal antibodies after the deposition of
aerosolized particles in the respiratory system. J. Control. Release 196, 344–354.
doi: 10.1016/j.jconrel.2014.10.003
Hartmann, T., Sasse, C., Schedler, A., Hasenberg, M., Gunzer, M., and
Krappmann, S. (2011). Shaping the fungal adaptome - stress responses of
Aspergillus fumigatus. Int. J. Med. Microbiol. 301, 408–416. doi: 10.1016/j.ijmm.
2011.04.008
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto,
A. C., et al. (2009). Frequency and evolution of azole resistance in Aspergillus
fumigatus associated with treatment failure. Emerg. Infect. Dis. 15, 1068–1076.
doi: 10.3201/eid1507.090043
Jacobs, D. M., Beyda, N. D., Asuphon, O., Jahangir Alam, M. J., and Garey, K. W.
(2015). Host factors and clinical outcomes of candida colonization in critically
Ill patients. Mycopathologia 179, 87–93. doi: 10.1007/s11046-014-9809-6
Jäger, V., Büssow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., et al. (2013).
High level transient production of recombinant antibodies and antibody fusion
proteins in HEK293 cells. BMC Biotechnol. 13:52. doi: 10.1186/1472-6750-
13-52
Kuhn, P., Fühner, V., Unkauf, T., Moreira, G. M. S. G., Frenzel, A., Miethe, S., et al.
(2016). Recombinant antibodies for diagnostics and therapy against pathogens
and toxins generated by phage display. Proteomics Clin. Appl. 10, 922–948.
doi: 10.1002/prca.201600002
Latgé, J.-P. (1999). Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12,
310–350.
Leach, M. D., and Brown, A. J. P. (2012). Posttranslational modifications of
proteins in the pathobiology of medically relevant fungi. Eukaryot. Cell 11,
98–108. doi: 10.1128/EC.05238-11
Li, J., Zhang, C., Jostock, T., and Dübel, S. (2007). Analysis of IgG heavy chain
to light chain ratio with mutant Encephalomyocarditis virus internal ribosome
entry site. Protein Eng. Des. Sel. 20, 491–496. doi: 10.1093/protein/gzm038
Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., Thiébaut, A., Le Strat, Y.,
et al. (2013). Épidémiologie de l’aspergillose invasive en France: résultat du
réseau SAIF (2005-2007). Bull. épidémiologique Hebd. 12–13, 121–124.
Maloney, D. G., Smith, B., and Rose, A. (2002). Rituximab: mechanism of action
and resistance. Semin. Oncol. 29, 2–9. doi: 10.1053/SONC.2002.30156
Matthews, R., Hodgetts, S., and Burnie, J. (1995). Preliminary assessment of
a human recombinant antibody fragment to hsp90 in murine invasive
candidiasis. J. Infect. Dis. 171, 1668–1671.
Mayr, L. M., Decoville, T., Schmidt, S., Laumond, G., Klingler, J., Ducloy, C., et al.
(2017). Non-neutralizing antibodies targeting the V1V2 domain of HIV exhibit
strong antibody-dependent cell-mediated cytotoxic activity. Sci. Rep. 7:12655.
doi: 10.1038/s41598-017-12883-6
Mazan, M., Blanco, N., Kovacova, K., Firakova, Z., Rehulka, P., Farkas, V.,
et al. (2013). A novel fluorescence assay and catalytic properties of Crh1 and
Crh2 yeast cell wall transglycosylases. Biochem. J. 455, 307–318. doi: 10.1042/
BJ20130354
Medici, N. P., and Poeta, M. D. (2015). New insights on the development of fungal
vaccines: from immunity to recent challenges. Mem. Inst. Oswaldo Cruz 110,
966–973. doi: 10.1590/0074-02760150335
Morton, D. B., and Griffiths, P. H. (1985). Guidelines on the recognition of
pain, distress and discomfort in experimental animals and an hypothesis for
assessment. Vet. Rec. 116, 431–436.
Nair, A. B., and Jacob, S. (2016). A simple practice guide for dose conversion
between animals and human. J. Basic Clin. Pharm. 7, 27–31. doi: 10.4103/0976-
0105.177703
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M.,
Meng, E. C., et al. (2004). UCSF Chimera - a visualization system for exploratory
research and analysis. J. Comput. Chem. 25, 1605–1612. doi: 10.1002/jcc.20084
Pitarch, A., Nombela, C., and Gil, C. (2008). Cell wall fractionation for yeast and
fungal proteomics. Methods Mol. Biol. 425, 217–239. doi: 10.1007/978-1-60327-
210-0_19
Porter, P. C., Lim, D. J., Maskatia, Z. K., Mak, G., Tsai, C. L., Citardi, M. J.,
et al. (2014). Airway surface mycosis in chronic TH2-associated airway disease.
J. Allergy Clin. Immunol. 134, 325.e9–331.e9. doi: 10.1016/j.jaci.2014.04.028
Ramadan, G., Davies, B., Kurup, V. P., and Keever-Taylor, C. A. (2005). Generation
of cytotoxic T cell responses directed to human leucocyte antigen Class I
restricted epitopes from the Aspergillus f16 allergen. Clin. Exp. Immunol. 140,
81–91. doi: 10.1111/j.1365-2249.2005.02738.x
Respaud, R., Vecellio, L., Diot, P., and Heuzé-Vourc’h, N. (2015). Nebulization as a
delivery method for mAbs in respiratory diseases. Expert Opin. Drug Deliv. 12,
1027–1039. doi: 10.1517/17425247.2015.999039
Richie, D. L., Ghannoum, M. A., Isham, N., Thompson, K. V., and Ryder, N. S.
(2012). Nonspecific effect of Mycograb on amphotericin B MIC. Antimicrob.
Agents Chemother. 56, 3963–3964. doi: 10.1128/AAC.00435-12
Rivera, A., and Pamer, E. G. (2009). “CD4+ T-cell responses to Aspergillus
fumigatus,” in Aspergillus fumigatus and Aspergillosis, eds J.-P. Latgé and W. J.
Steinbach (Washington, DC: American Society of Microbiology), 263–277.
Rivera, A., Van Epps, H. L., Hohl, T. M., Rizzuto, G., and Pamer, E. G. (2005).
Distinct CD4 + -T-cell responses to live and heat-inactivated Aspergillus
fumigatus conidia. Infect. Immun. 73, 7170–7179. doi: 10.1128/IAI.73.11.
7170
Schubert, M., Spiegel, H., Schillberg, S., and Nölke, G. (2018). Aspergillus-specific
antibodies – targets and applications. Biotechnol. Adv. 36, 1167–1184. doi: 10.
1016/j.biotechadv.2018.03.016
Schütte, M., Thullier, P., Pelat, T., Wezler, X., Rosenstock, P., Hinz, D., et al. (2009).
Identification of a putative Crf splice variant and generation of recombinant
antibodies for the specific detection of Aspergillus fumigatus. PLoS One 4:e6625.
doi: 10.1371/journal.pone.0006625
Sécher, T., Guilleminault, L., Reckamp, K., Amanam, I., Plantier, L., and Heuzé-
Vourc’h, N. (2018). Therapeutic antibodies: a new era in the treatment of
respiratory diseases? Pharmacol. Ther. 189, 149–172. doi: 10.1016/j.pharmthera.
2018.05.003
Frontiers in Microbiology | www.frontiersin.org 15 March 2019 | Volume 10 | Article 600
fmicb-10-00600 March 22, 2019 Time: 17:56 # 16
Chauvin et al. Anti-Crf Antibodies for Targeting Aspergillus fumigatus
Shields, R. L., Lai, J., Keck, R., O’Connell, L. Y., Hong, K., Gloria Meng, Y.,
et al. (2002). Lack of fucose on human IgG1 N-linked oligosaccharide
improves binding to human FcγRIII and antibody-dependent cellular
toxicity. J. Biol. Chem. 277, 26733–26740. doi: 10.1074/jbc.M20206
9200
Song, Y., Baer, M., Srinivasan, R., Lima, J., Yarranton, G., Bebbington, C.,
et al. (2012). PcrV antibody-antibiotic combination improves survival in
Pseudomonas aeruginosa-infected mice. Eur. J. Clin. Microbiol. Infect. Dis. 31,
1837–1845. doi: 10.1007/s10096-011-1509-2
Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson,
M. A., et al. (2003). Allergic bronchopulmonary aspergillosis in cystic fibrosis—
state of the art: cystic fibrosis foundation consensus conference. Clin. Infect. Dis.
37, S225–S264. doi: 10.1086/376525
Stuehler, C., Khanna, N., Bozza, S., Zelante, T., Moretti, S., Kruhm, M., et al.
(2011). Cross-protective T H 1 immunity against Aspergillus fumigatus
and Candida albicans. Blood 117, 5881–5891. doi: 10.1182/blood-2010-12-32
5084
Taccone, F., Van den Abeele, A.-M., Bulpa, P., Misset, B., Meersseman, W.,
Cardoso, T., et al. (2015). Epidemiology of invasive aspergillosis in critically ill
patients: clinical presentation, underlying conditions, and outcomes. Crit. Care
19:7. doi: 10.1186/s13054-014-0722-7
Thomann, M., Reckermann, K., Reusch, D., Prasser, J., and Tejada, M. L.
(2016). Fc-galactosylation modulates antibody-dependent cellular cytotoxicity
of therapeutic antibodies. Mol. Immunol. 73, 69–75. doi: 10.1016/j.molimm.
2016.03.002
Wagner, E. K., and Maynard, J. A. (2018). Engineering therapeutic antibodies to
combat infectious diseases. Curr. Opin. Chem. Eng. 19, 131–141. doi: 10.1016/j.
coche.2018.01.007
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P.,
Marr, K. A., et al. (2008). Treatment of aspergillosis: clinical practice guidelines
of the infectious diseases society of America. Clin. Infect. Dis. 46, 327–360.
doi: 10.1086/525258
Wartenberg, D., Lapp, K., Jacobsen, I. D., Dahse, H. M., Kniemeyer, O.,
Heinekamp, T., et al. (2011). Secretome analysis of Aspergillus fumigatus reveals
Asp-hemolysin as a major secreted protein. Int. J. Med. Microbiol. 301, 602–611.
doi: 10.1016/j.ijmm.2011.04.016
Willger, S., Grahl, N., and Cramer, R. A. (2009). Aspergillus fumigatus metabolism:
clues to mechanisms of in vivo fungal growth and virulence. Med. Mycol. 47,
72–79. doi: 10.1080/13693780802455313
Conflict of Interest Statement: NH-V is a founder and a business associate in a
CRO called Cynbiose Respiratory, which has no link with the project mentioned
in this article.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Chauvin, Hust, Schütte, Chesnay, Parent, Moreira, Arroyo, Sanz,
Pugnière, Martineau, Chandenier, Heuzé-Vourc’h and Desoubeaux. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Microbiology | www.frontiersin.org 16 March 2019 | Volume 10 | Article 600
